Proton therapy for brain tumors
Official title: Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology
Run by Maastricht Radiation Oncology · NCT04648462 · Data updated 2026-11-12
This study is testing whether proton therapy can be a better treatment option for patients with certain brain tumors by comparing it to traditional radiation methods to see if it can reduce harm to healthy tissues.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1500 (estimated) |
| Sponsor | Maastricht Radiation Oncology Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 3 sites (Maastricht, Limburg and 2 other locations) |
| Status | Recruiting |
| Started | January 1, 2018 |
| Main results expected | January 1, 2030 |
| Study ends | January 1, 2035 |
| Registry record updated | October 13, 2026 |
| Trial ID | NCT04648462 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with brain tumors that have a favorable prognosis and minimal neurocognitive impairment.
✕Probably not a fit
Patients who are not eligible for chemotherapy or are suitable for stereotactic radiotherapy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on the application of proton therapy for patients with specific brain tumors, including astrocytoma and oligodendroglioma. It utilizes a model-based approach to compare proton and photon treatment plans for individual patients, assessing the potential reduction in radiation dose to healthy tissues and the expected clinical benefits. The study aims to identify patients who would benefit most from proton therapy by analyzing dosimetric gains and normal tissue complication probabilities. The research is conducted across multiple leading medical centers in the Netherlands.
Why it matters
Potential benefit: If successful, this approach could lead to reduced radiation-induced complications and improved outcomes for patients with brain tumors.
How similar studies have gone: Other studies have shown promise in using proton therapy for similar conditions, indicating a growing body of evidence supporting this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. All brain tumors with a favorable prognosis (median survival \> 10 year) 2. Age ≥ 18 years 3. ECOG performance status 0 - 1 / Karnofsky performance status 80 - 100 4. No - minimal neurocognitive impairment 5. Dosimetrical gain of protontherapy relative to photontherapy (≥5% on supratentorial brain dose or hippocampi) 6. Informed consent Exclusion Criteria: 1. Not eligible for chemotherapy 2. Eligible for stereotactic radiotherapy
Where it's running
-
Maastricht Radiation Oncology
Maastricht, Limburg, Netherlands Recruiting -
Universitair Medisch Centrum Groningen
Groningen, Provincie Groningen, Netherlands Recruiting -
Holland PTC
Delft, South Holland, Netherlands Recruiting
Study contacts
- Principal investigator: Danielle Eekers — Maastro Clinic, The Netherlands
- Study coordinator: Danielle Eekers
- Email: danielle.eekers@maastro.nl
- Phone: +31884455600
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pre-radiation chemotherapy for high-grade glioma
Researchers are testing whether giving temozolomide before radiation can help patients with newly diagnosed high-grade gliomas see better outcomes and clearer MRI results after treatment.
-
FearLess for adults with malignant brain tumors and their caregivers
This project will test whether the FearLess psychological program can reduce fear of cancer recurrence in adults with primary malignant brain tumors and their nonprofessional caregivers.
-
Home-based self-management and cognitive training for brain tumor survivors
This trial will try a home-based cognitive coaching program to see if it improves thinking and quality of life for adults who survived non-glioblastoma brain tumors, with optional caregiver participation.
-
Investigating the effects of endoscopic skull base surgery on smell
This study tests how endoscopic skull base surgery affects the sense of smell in patients to better understand any smell-related problems that might happen after the surgery.
-
Pharmacoscopy-guided treatment for refractory brain tumors
This trial tests whether personalized drug testing on a patient’s tumor cells can guide treatment choices for adults with hard-to-treat brain cancers like glioblastoma.
-
Combining Lutathera® and Olaparib for treating recurrent solid tumors in children and adolescents
This study is testing if combining Lutathera® with olaparib can help children and teenagers with hard-to-treat solid tumors that have certain receptors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.